PIERIS PHARMACEUTICALS, INC. (38) | Uncategorized (7)
Recent Contracts
-
Combination Study Agreement, dated March 24, 2021, by and among Pieris Pharmaceuticals, Inc. and Seagen Inc
(Filed With SEC on May 17, 2021)
-
Amendment No. 1 to the February 8, 2018 Platform Agreement by and among Pieris Pharmaceuticals, Inc. and Pieris Pharmaceuticals GmbH and Seattle Genetics, Inc
(Filed With SEC on August 10, 2020)
-
Pieris Pharmaceuticals, Inc. 2020 Employee, Director and Consultant Equity Incentive Plan
(Filed With SEC on June 29, 2020)
-
Description of Registered Securities
(Filed With SEC on March 13, 2020)
-
Letter Agreement by and between the Registrant and Louis A. Matis, M.D., dated as of January 8, 2020
(Filed With SEC on March 13, 2020)
-
Open Market Sale Agreement, dated as of August 9, 2019, by and between Pieris Pharmaceuticals, Inc. and Jefferies LLC
(Filed With SEC on August 9, 2019)
-
Subtenant Recognition and Attornment Agreement, by and among Pieris Pharmaceuticals, Inc., 225 State Street, LLC, and Berenberg Capital Markets LLC, dated as of May 31, 2019
(Filed With SEC on August 9, 2019)